ImCheck Therapeutics’ Post

This study compares the effects of neoadjuvant immune-oncology (IO) based regimens on patients with renal cell carcinoma (RCC) with and without tumor thrombus. Listen to Wadih Issa from UT Southwestern present the results of the study in this MEDtalk from ASCO GU 2024. #ASCOGU24 #KidneyCancer #Oncology

In a study published in the most recent issue of Melanoma Research, it was found that 223 of 567, or almost 40%, of patients who received surgical resection saw melanoma recurrence, or the return of their initial cancer, after a 39-month interval. The study gives further insight into long-term results of melanoma treatment, including the rate of distant metastasis, real-world distant metastasis-free survival (rwDMFS) rates, and more. Read the full study at the link below: https://lnkd.in/gN8kHA7Y #Oncology #HealthTrials #RWD

This study compares the effects of neoadjuvant immune-oncology (IO) based regimens on patients with renal cell carcinoma (RCC) with and without tumor thrombus. Listen to Wadih Issa from UT Southwestern present the results of the study in this MEDtalk from ASCO GU 2024. #ASCOGU24 #KidneyCancer #Oncology

#BreakingNews: The first patient has been enrolled in our Phase 2 expansion study evaluating ST316, our first-in-class antagonist of β-catenin (NCT05848739). ST316 selectively shuts down the Wnt/β-catenin signaling pathway in tumor cells but not in normal cells, allowing for anti-cancer activity without the toxicity related to broad inhibition of this pathway. The Wnt/β-catenin signaling pathway is one of the most active pathways in several cancers and drives more than 80% of colorectal cancers – the first indication to be assessed in our Phase 2 expansion study. Click here to learn more: https://lnkd.in/gyqWuTMx #Colorectalcancer #ClinicalTrials #Oncology #DrugDevelopment

This study compares the effects of neoadjuvant immune-oncology (IO) based regimens on patients with renal cell carcinoma (RCC) with and without tumor thrombus. Listen to Wadih Issa from UT Southwestern present the results of the study in this MEDtalk from ASCO GU 2024. #ASCOGU24 #KidneyCancer #Oncology

This study compares the effects of neoadjuvant immune-oncology (IO) based regimens on patients with renal cell carcinoma (RCC) with and without tumor thrombus. Listen to Wadih Issa, MD from UT Southwestern present the results of the study in this MEDtalk from ASCO GU 2024. #ASCOGU24 #KidneyCancer #Oncology

At #ESMO24, we unveiled results from a new study showing how PARP inhibitors (PARPi) can benefit patients with ovarian, pancreatic, prostate, and triple-negative breast cancers. Using Cellworks personalized therapy biosimulation, we identified homologous recombination deficiency(HRD) beyond BRCA mutation status, providing more comprehensive predictions of patient response to PARPi therapies. A special thank you to Dr. Daniel Palmer, Principal Investigator of the study, for his work with us and advancing personalized therapy for cancer patients. You can read details about the study here - https://lnkd.in/gDeawZj7 #ESMO24 #PersonalizedMedicine #Biosimulation #Oncology #Cellworks

🚨Highlights from ESMO 2024! Dr Pieterjan Vanclooster, resident in medical oncology at University Hospital Antwerp, shares key findings from the proffered paper session: - Phase 3 NPC Trial: A new treatment approach reduces severe toxicity in nasopharyngeal carcinoma. - TACTI-003 Trial: Combination immunotherapy shows promise in recurrent head and neck cancer. - Safety Profile: No new safety signals observed with combination therapy. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #HeadAndNeckCancer #Oncology #CancerResearch #ClinicalTrials

Scorpion is honored to support #BreastCancerAwarenessMonth and share the promising results from our recent clinical study presented at #ESMO. Our Phase 1/2 trial of STX-478 demonstrates potentially best-in-class PI3Kα inhibition, showing a 23% overall response rate in HR+/HER2- metastatic breast cancer, and significant tumor reductions in patients with advanced solid tumors. Our early, differentiated signals of monotherapy efficacy compare favorably to other pathway inhibitors. This milestone reflects our unwavering commitment to improving patients' lives through next-generation precision oncology. Learn more about our findings and ongoing efforts: https://bit.ly/3Y4iB25

Shortly commencing OV Precision Trial has now been registered at clinicaltrials.gov. It will be a landmark trial, applying precision oncological decision making using Tumor Profiler Center #TPC technologies in newly diagnosed ovarian cancer patients. HRD testing will examine the most desperate non-HRD patients, from whom we already know ow that they won’t respond to standard chemotherapy. Alternative information from TPC technologies will generate information for tge treating oncologist and allow alternative treatment decisions. #SwissGO. Swiss-GO - Designing innovative out-of-the-box trials in Gynecological Oncology